A critical appraisal of advances in pediatric nonalcoholic fatty liver disease

Seminars in Liver Disease

Volumn 32, Issue 4, 2012, Pages 317-324

  Ovchinsky, Nadia ^a   Lavine, Joel E ^a  

^a Columbia University ^*  (United States)

Author keywords

nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); obesity; pediatrics

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ALPHA TOCOPHEROL; APOLIPOPROTEIN A1; BILIRUBIN; CYTOKERATIN 18; DOCOSAHEXAENOIC ACID; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LEPTIN; MERCAPTAMINE; METFORMIN; PIOGLITAZONE; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL TENDERNESS; ACANTHOSIS NIGRICANS; AEROBIC EXERCISE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ASYMPTOMATIC DISEASE; BARIATRIC SURGERY; BODY MASS; CALORIC RESTRICTION; COMPUTER ASSISTED TOMOGRAPHY; CYSTINOSIS; DRUG MEGADOSE; DYSLIPIDEMIA; ELASTOGRAPHY; GENETIC RISK; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; SPLENOMEGALY; ULTRASOUND; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION;

ANTIOXIDANTS; BIOPSY, LARGE-CORE NEEDLE; CHILD; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OBESITY; RISK FACTORS; WEIGHT REDUCTION PROGRAMS;

EID: 84873400247     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1329905     Document Type: Article

References (102)

1. Ogden C. L., Carroll M. D., Curtin L. R., Lamb M. M., Flegal K. M. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA: 2010; 303 3 242 249
2. Schwimmer J. B., Behling C., Newbury R., et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology: 2005; 42 3 641 649 (Pubitemid 41233657)
3. Brunt E. M. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol: 2010; 7 4 195 203
4. Schwimmer J. B., Pardee P. E., Lavine J. E., Blumkin A. K., Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation: 2008; 118 3 277 283
5. Riley M. R., Bass N. M., Rosenthal P., Merriman R. B. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr: 2005; 147 6 839 842 (Pubitemid 41774844)
6. Schwimmer J. B., Dunn W., Norman G. J., et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology: 2010; 138 4 1357 1364, 1364, e1-e2
7. Manco M., Bedogni G., Marcellini M., et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut: 2008; 57 9 1283 1287
8. Manco M., Marcellini M., Devito R., et al. Metabolic syndrome and liver histology in paediatric nonalcoholic steatohepatitis. Int J Obes: 2008; 32 381 387 (Pubitemid 351271778)
9. Fraser A., Longnecker M. P., Lawlor D. A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology: 2007; 133 6 1814 1820 (Pubitemid 350186161)
10. Wiegand S., Keller K. M., Röbl M., et al. APV-Study Group and the German Competence Network Adipositas Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16,390 overweight or obese children and adolescents. Int J Obes (Lond): 2010; 34 10 1468 1474
11. Schwimmer J. B., Deutsch R., Kahen T., Lavine J. E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics: 2006; 118 4 1388 1393 (Pubitemid 46393782)
12. Patton H. M., Lavine J. E., Van Natta M. L., Schwimmer J. B., Kleiner D., Molleston J. Nonalcoholic Steatohepatitis Clinical Research Network Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology: 2008; 135 6 1961 1971, e2
13. Barlow S. E. Expert Committee Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics: 2007; 120 04 S164 S192
14. Chalasani N., Younossi Z., Lavine J. E., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology: 2012; 55 6 2005 2023
15. Feldstein A. E., Charatcharoenwitthaya P., Treeprasertsuk S., Benson J. T., Enders F. B., Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut: 2009; 58 11 1538 1544
16. Argo C. K., Northup P. G., Al-Osaimi A. M., Caldwell S. H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol: 2009; 51 2 371 379
17. Ascha M. S., Hanouneh I. A., Lopez R., Tamimi T. A., Feldstein A. F., Zein N. N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology: 2010; 51 6 1972 1978
18. Starley B. Q., Calcagno C. J., Harrison S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology: 2010; 51 5 1820 1832
19. Sanyal A., Poklepovic A., Moyneur E., Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin: 2010; 26 9 2183 2191
20. Argo C. K., Caldwell S. H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis: 2009; 13 4 511 531
21. Caserta C. A., Pendino G. M., Amante A., et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol: 2010; 171 11 1195 1202
22. Demirciolu F., Koçyiit A., Arslan N., Cakmakçi H., Hizli S., Sedat A. T. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr: 2008; 47 1 68 75
23. Pacifico L., Cantisani V., Ricci P., et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res: 2008; 63 4 423 427 (Pubitemid 351450591)
24. Pacifico L., Anania C., Martino F., et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology: 2010; 52 5 1643 1651
25. Kleiner D. E., Brunt E. M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology: 2005; 41 6 1313 1321 (Pubitemid 40770284)
26. Wong V. W., Wong G. L., Choi P. C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut: 2010; 59 7 969 974
27. Carter-Kent C., Yerian L. M., Brunt E. M., et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology: 2009; 50 4 1113 1120
28. Nobili V., Pinzani M. Paediatric non-alcoholic fatty liver disease. Gut: 2010; 59 5 561 564
29. Pacifico L., Celestre M., Anania C., Paolantonio P., Chiesa C., Laghi A. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr: 2007; 96 4 542 547 (Pubitemid 46466114)
30. Schwimmer J. B., Celedon M. A., Lavine J. E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology: 2009; 136 5 1585 1592
31. Nguyen D., Talwalkar J. A. Noninvasive assessment of liver fibrosis. Hepatology: 2011; 53 6 2107 2110
32. Nobili V., Vizzutti F., Arena U., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology: 2008; 48 2 442 448
33. de Lédinghen V., Le Bail B., Rebouissoux L., et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr: 2007; 45 4 443 450 (Pubitemid 350307163)
34. Rockey D. C., Bissell D. M. Noninvasive measures of liver fibrosis. Hepatology: 2006; 43 2 01 S113 S120
35. Huwart L., Sempoux C., Vicaut E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology: 2008; 135 1 32 40 (Pubitemid 351899024)
36. Yin M., Talwalkar J. A., Glaser K. J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol: 2007; 5 10 1207 1213, e2
37. Chen J., Talwalkar J. A., Yin M., Glaser K. J., Sanderson S. O., Ehman R. L. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology: 2011; 259 3 749 756
38. Imbert-Bismut F., Messous D., Thibault V., et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med: 2004; 42 3 323 333 (Pubitemid 38477529)
39. Friedrich-Rust M., Rosenberg W., Parkes J., Herrmann E., Zeuzem S., Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol: 2010; 10 103
40. Halfon P., Bourliere M., Deydier R., et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol: 2006; 101 3 547 555 (Pubitemid 43340931)
41. Guha I. N., Parkes J., Roderick P., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology: 2008; 47 2 455 460 (Pubitemid 351280713)
42. Nobili V., Parkes J., Bottazzo G., et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology: 2009; 136 1 160 167
43. Feldstein A. E., Wieckowska A., Lopez A. R., Liu Y. C., Zein N. N., McCullough A. J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology: 2009; 50 4 1072 1078
44. Seidel N., Volkmann X., Länger F., et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology: 2005; 42 1 113 120 (Pubitemid 40911318)
45. Valva P., De Matteo E., Galoppo M. C., Gismondi M. I., Preciado M. V. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol: 2010; 82 6 949 957
46. Joka D., Wahl K., Moeller S., et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology: 2012; 55 2 455 464
47. Adams L. A. Biomarkers of liver fibrosis. J Gastroenterol Hepatol: 2011; 26 5 802 809
48. Bell L. N., Theodorakis J. L., Vuppalanchi R., et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology: 2010; 51 1 111 120
49. Morra R., Munteanu M., Bedossa P., et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther: 2007; 26 6 847 858 (Pubitemid 47346704)
50. Poon T. C., Hui A. Y., Chan H. L., et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem: 2005; 51 2 328 335 (Pubitemid 40175802)
51. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol: 2008; 48 6 993 999
52. Lindbäck S. M., Gabbert C., Johnson B. L., et al. Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr: 2010; 57 1 85 140
53. Cohen J. C., Horton J. D., Hobbs H. H. Human fatty liver disease: old questions and new insights. Science: 2011; 332 6037 1519 1523
54. Lim J. S., Mietus-Snyder M., Valente A., Schwarz J. M., Lustig R. H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol: 2010; 7 5 251 264
55. Nielsen S. J., Popkin B. M. Changes in beverage intake between 1977 and 2001. Am J Prev Med: 2004; 27 3 205 210 (Pubitemid 39278319)
56. Hu F. B., Malik V. S. Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence. Physiol Behav: 2010; 100 1 47 54
57. Vega G. L., Chandalia M., Szczepaniak L. S., Grundy S. M. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology: 2007; 46 3 716 722 (Pubitemid 47436117)
58. Tilg H., Moschen A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology: 2010; 52 5 1836 1846
59. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab: 2007; 293 4 E1118 E1128 (Pubitemid 47535846)
60. Polyzos S. A., Kountouras J., Zavos C., Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol: 2011; 45 1 50 54
61. Choi S. S., Syn W. K., Karaca G. F., et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem: 2010; 285 47 36551 36560
62. De Minicis S., Seki E., Oesterreicher C., Schnabl B., Schwabe R. F., Brenner D. A. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology: 2008; 48 6 2016 2026
63. Wang S. N., Lee K. T., Ker C. G. Leptin in hepatocellular carcinoma. World J Gastroenterol: 2010; 16 46 5801 5809
64. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis: 2010; 28 1 179 185
65. Pagano C., Soardo G., Esposito W., et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol: 2005; 152 1 113 118 (Pubitemid 40185459)
66. Pisto P., Ukkola O., Santaniemi M., Kesäniemi Y. A. Plasma adiponectin-an independent indicator of liver fat accumulation. Metabolism: 2011; 60 11 1515 1520
67. Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol: 2010; 44 01 S16 S18
68. Abu-Shanab A., Quigley E. M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol: 2010; 7 12 691 701
69. Burke C. A. Colonic complications of obesity. Gastroenterol Clin North Am: 2010; 39 1 47 55
70. Spruss A., Kanuri G., Wagnerberger S., Haub S., Bischoff S. C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology: 2009; 50 4 1094 1104
71. Harte A. L., da Silva N. F., Creely S. J., et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond): 2010; 7 15
72. Dasu M. R., Devaraj S., Park S., Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care: 2010; 33 4 861 868
73. Alisi A., Manco M., Devito R., Piemonte F., Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr: 2010; 50 6 645 649
74. Schwimmer J. B., Celedon M. A., Lavine J. E., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology: 2009; 136 5 1585 1592
75. Rotman Y., Koh C., Zmuda J. M., Kleiner D. E., Liang T. J. NASH CRN The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology: 2010; 52 3 894 903
76. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet: 2008; 40 12 1461 1465
77. Romeo S., Sentinelli F., Cambuli V. M., et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol: 2010; 53 2 335 338
78. Sookoian S., Pirola C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology: 2011; 53 6 1883 1894
79. Speliotes E. K., Yerges-Armstrong L. M., Wu J., et al. NASH CRN; GIANT Consortium; MAGIC Investigators; GOLD Consortium Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet: 2011; 7 3 e1001324
80. Torres D. M., Harrison S. A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology: 2008; 134 6 1682 1698 (Pubitemid 351615413)
81. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia: 2012; 55 4 885 904
82. Thoma C., Day C. P., Trenell M. I. Lifestyle interventions for the treatment of nonalcoholic fatty liver disease in adults: a systematic review. J Hepatol: 2012; 2012 56 255 266
83. Sato F., Tamura Y., Watada H., et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab: 2007; 92 8 3326 3329 (Pubitemid 47236409)
84. Keating S. E., Hackett D. A., George J., Johnson N. A. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol: 2012; 57 1 157 166
85. Nobili V., Marcellini M., Devito R., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology: 2006; 44 2 458 465 (Pubitemid 44214885)
86. Gronbæk H., Lange A., Birkebæk N. H., et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr: 2012; 54 2 223 228
87. Barker K. B., Palekar N. A., Bowers S. P., Goldberg J. E., Pulcini J. P., Harrison S. A. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol: 2006; 101 2 368 373 (Pubitemid 43381682)
88. Pardee P. E., Lavine J. E., Schwimmer J. B. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg: 2009; 18 3 144 151
89. Weiner R. A. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis: 2010; 28 1 274 279
90. Nadler E. P., Youn H. A., Ren C. J., Fielding G. A. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg: 2008; 43 1 141 146
91. Nadler E. P., Reddy S., Isenalumhe A., et al. Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. J Am Coll Surg: 2009; 209 5 638 644
92. Klein-Platat C., Drai J., Oujaa M., Schlienger J. L., Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr: 2005; 82 6 1178 1184 (Pubitemid 43779715)
93. Capanni M., Calella F., Biagini M. R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther: 2006; 23 8 1143 1151 (Pubitemid 43779354)
94. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis: 2008; 40 3 194 199 (Pubitemid 351181793)
95. Nobili V., Bedogni G., Alisi A., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child: 2011; 96 4 350 353
96. Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
97. Lavine J. E., Schwimmer J. B., Van Natta M. L., et al. Nonalcoholic Steatohepatitis Clinical Research Network Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA: 2011; 305 16 1659 1668
98. Dohil R., Fidler M., Gangoiti J. A., Kaskel F., Schneider J. A., Barshop B. A. Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr: 2010; 156 1 71 75, e1-e3
99. Lu S. C. Regulation of glutathione synthesis. Mol Aspects Med: 2009; 30 1-2 42 59
100. Dohil R., Schmeltzer S., Cabrera B. L., et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther: 2011; 33 9 1036 1044
101. Dohil R., Meyer L., Schmeltzer S., Cabrera B. L., Lavine J. E., Phillips S. A. The Effect of Cysteamine Bitartrate on Adiponectin Multimerization in Non-Alcoholic Fatty Liver Disease and Healthy Subjects. J Pediatr: 2012;. [Epub ahead of print]
102. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH study to test treatment of fatty liver disease in children. Available at: http://www.nih.gov/news/health/jan2012/niddk-11.htm. Accessed January 30, 2012